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ABSTRACT
Objective The study evaluates the relationship of 
coronary stenosis, atherosclerotic plaque characteristics 
(APCs) and age using artificial intelligence enabled 
quantitative coronary computed tomographic angiography 
(AI- QCT).
Methods This is a post- hoc analysis of data from 
303 subjects enrolled in the CREDENCE (Computed 
TomogRaphic Evaluation of Atherosclerotic Determinants of 
Myocardial IsChEmia) trial who were referred for invasive 
coronary angiography and subsequently underwent 
coronary computed tomographic angiography (CCTA). In 
this study, a blinded core laboratory analysing quantitative 
coronary angiography images classified lesions as 
obstructive (≥50%) or non- obstructive (<50%) while AI 
software quantified APCs including plaque volume (PV), 
low- density non- calcified plaque (LD- NCP), non- calcified 
plaque (NCP), calcified plaque (CP), lesion length on a 
per- patient and per- lesion basis based on CCTA imaging. 
Plaque measurements were normalised for vessel volume 
and reported as % percent atheroma volume (%PAV) for 
all relevant plaque components. Data were subsequently 
stratified by age <65 and ≥65 years.
Results The cohort was 64.4±10.2 years and 29% 
women. Overall, patients >65 had more PV and CP than 
patients <65. On a lesion level, patients >65 had more 
CP than younger patients in both obstructive (29.2 mm3 
vs 48.2 mm3; p<0.04) and non- obstructive lesions (22.1 
mm3 vs 49.4 mm3; p<0.004) while younger patients had 
more %PAV (LD- NCP) (1.5% vs 0.7%; p<0.038). Younger 
patients had more PV, LD- NCP, NCP and lesion lengths in 
obstructive compared with non- obstructive lesions. There 
were no differences observed between lesion types in 
older patients.
Conclusion AI- QCT identifies a unique APC signature 
that differs by age and degree of stenosis and provides 
a foundation for AI- guided age- based approaches to 
atherosclerosis identification, prevention and treatment.
INTRODUCTION
Coronary computed tomographic angiog-
raphy (CCTA) has been validated as a non- 
invasive imaging modality capable of both 
ruling out coronary artery disease (CAD) 
and quantifying coronary plaque.1 2 Advance-
ments in the diagnostic specificity of CCTA 
have allowed not only for quantification of 
total plaque through the entirety of coronary 
vascular anatomy, but also for the specific 
identification and quantification of various 
plaque characteristics in stable and unstable 
lesions.3 This capability along with the use 
of artificial intelligence (AI) and machine 
Key questions
What is already known about this subject?
 ► High- risk atherosclerotic plaque characteristics 
put patients at risk for cardiovascular events, but 
is challenging for clinical practice using currently 
available methods.
What does this study add?
 ► This study provides a lesion- based assessment of 
plaque changes by age.
 ► This study provides support for use of artificial in-
telligence enabled quantitative coronary computed 
tomographic angiography (AI- QCT) to identify an age 
associated plaque phenotype.
How might this impact on clinical practice?
 ► These findings provide clinicians with an opportunity 
to tailor patient treatment based on the risk associ-
ated with a patient’s plaque profile.
 ► These findings provide a basis for evaluating pa-
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learning have resulted in an expanding foundation of 
data describing high risk atherosclerotic plaque charac-
teristics (APCs) that put specific patient populations at 
increased risk for major adverse cardiovascular events 
(MACE).4 Several APCs, namely, total plaque volume 
(PV), low density non- calcified plaque (LD- NCP), non- 
calcified plaque (NCP), calcified plaque (CP) and lesion 
length have been identified as significant quantifiable 
characteristics with prognostic value.5 6 The per cent 
atheroma volume (PAV) reflects each APC’s quantity after 
normalising for vessel volume and has been suggested as a 
way of calculating and reporting APCs. Other significant 
quantifiable markers included vascular positive remodel-
ling (PR), spotty calcification (SC), napkin- ring sign and 
high- risk plaque (HRP), defined as coronary lesions with 
both LD- NCP and PR.5 7–9 There have been distinct differ-
ences in the characteristics of these plaques based on 
various demographic and clinical variables, but whether 
these characteristics vary by age is still being investigated. 
This study intended to identify whether obstructive and 
non- obstructive lesions have different plaque character-
istics based on age, specifically in individuals older than 
65 compared with those younger than 65 years through 
plaque quantification using AI enabled quantitative coro-
nary computed tomographic angiography (AI- QCT).
METHODS
The study population was comprised of the derivation 
cohort of the Computed TomogRaphic Evaluation of 
Atherosclerotic Determinants of Myocardial IsChEmia 
(CREDENCE) trial ( ClinicalTrials. gov, NCT02173275), 
which was a prospective, multicentre diagnostic deriva-
tion–validation controlled clinical trial recruiting stable 
patients from 2014 to 2017. Sites and Investigators are 
listed in online supplemental appendix A. A detailed 
design manuscript was previously published.10 Enrolled 
patients underwent CCTA followed by invasive quanti-
tative coronary angiography as the reference test within 
60 days. Eligibility criteria included referral to non- 
emergent invasive coronary angiography (ICA) based 
on the American College of Cardiology/American 
Heart Association clinical practice guidelines for stable 
ischaemic heart disease. All index tests were interpreted 
in blinded fashion by an imaging core laboratory. Patient 
demographics, cardiovascular risk factors, laboratory 
values and medications were prospectively collected and 
recorded at the time of baseline and follow- up CCTAs.
CCTA imaging protocols
CCTA was performed using single or dual source CT 
scanners of ≥64- detector rows. Sites performed CCTA in 
accordance with the guidelines established by the Society 
of Cardiovascular Computed Tomography (SCCT).11 
Nitroglycerin was administered immediately prior to 
CCTA to enhance imaging quality. Image quality for 
CCTA was acceptable in 99% of patients.
AI enabled quantification of CCTA
The AI- based approach to CCTA interpretation in this 
study was performed using a validated and US Food and 
Drug Administration (FDA)- cleared software service 
(Cleerly Inc, New York, New York) that performs auto-
mated analysis of CCTA using a series of validated convo-
lutional neural network models (including VGG19 
network, 3D U- Net and VGG Network Variant) for image 
quality assessment, coronary segmentation and labelling, 
lumen wall evaluation and vessel contour determination 
and plaque characterisation.12 13 The centerline algorithm 
was developed from 1 007 945 images, which comprised 
23 068 vessels from 3671 patients (online supplemental 
appendix B). The lumen and vessel wall algorithms were 
developed from 1 414 877 images, which comprised 8555 
vessels from 3676 patients. First, the AI- aided approach 
produces a centerline along each coronary artery, and 
then for lumen and outer vessel wall contouring. This is 
applied to each phase of the examination and the two 
optimal series are identified for further analysis. After 
establishing vessel wall contours, distance and volumetric 
analyses were performed based on specified Hounsfield 
unit (HU) cut offs for characterising plaque character-
istics. After the AI algorithm has finished all operations, 
as mandated by the FDA, a quality control cardiac CT 
trained technician reviews the results of the AI analysis in 
all cases with manual adjustment if necessary.
Coronary segments with a diameter ≥2 mm were 
included in the analysis using the modified 18- segment 
SCCT model.14 Each segment was evaluated for the pres-
ence or absence of coronary atherosclerosis, defined as any 
tissue structure >1 mm2 within the coronary artery wall that 
was differentiated from the surrounding epicardial tissue, 
epicardial fat or the vessel lumen itself. The following APCs 
were evaluated:
 ► Atherosclerosis: Quantitative atherosclerosis charac-
terisation was performed for every coronary artery 
and its branches using the automated AI- enabled 
web- based software platform (Cleerly Labs).13 PVs 
(mm3) were calculated for each coronary lesion and 
then summated to compute the PV at the patient 
level. Plaque with a minimum volume of ≥3 mm3 was 
included for analysis. This provided data for analysis 
on both the lesion and patient level. PV was further 
categorised using HU ranges with NCP defined as 
30–350 HU; LD- NCP defined as plaques <30 HU; and 
CP defined as >350 HU. Coronary plaque burden 
was normalised to vessel volume to account for 
natural variation in coronary artery volume. Plaque 
burden was reported as PAV, CP PAV, NCP PAV and 
LD- NCP PAV which was calculated as PV (by each 
aforementioned type)/vessel volume×100%. Figure 1 
provides an example of the software output for a 
patient with an obstructive left anterior descending 
(LAD) lesion predominantly comprised of NCP and 
LD- NCP. Figure 2 reflects the AI generated analysis 
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and LD- NCP while figure 3 provides an example of an 
right coronary artery (RCA) lesion comprised mostly 
of calcified plaque.
 ► Vascular remodelling: Arterial remodelling was calcu-
lated by examining the lesion diameter divided by the 
normal reference diameter. PR was defined as a ratio 
Figure 1 A 39- year- old with coronary CT angiography (CCTA) undergoing artificial intelligence (AI)- aided evaluation of stenosis 
and quantitative atherosclerosis burden. The patient demonstrates left anterior descending coronary artery obstructive stenosis 
(82%) with a burden of plaque (352.5 mm3) consisting predominantly of non- calcified (321.8 mm3) that includes low- density 
non- calcified plaque (LD- NCP 30.5 mm3). (A) shows a CCTA straight reformat with plaque identified, while (B) shows a straight 
reformat with a colour overlay of non- calcified plaque (yellow), LD- NCP (red) and calcified plaque (blue). (C) shows a curved 
multiplanar reformat. (D) shows a graphical output of the quantified plaque volume by AI- aided evaluation. dLAD, distal left 
anterior descending; LM, left main; mLAD, mid left anterior descending; pLAD, proximal left anterior descending.
Figure 2 A 55- year- old with coronary CT angiography (CCTA) undergoing artificial intelligence (AI)- aided evaluation of stenosis 
and quantitative atherosclerosis burden. The patient demonstrates left anterior descending coronary artery non- obstructive 
stenosis (25%) with a burden of plaque (160.2 mm3) consisting predominantly of non- calcified (159.4 mm3) that includes non- 
negligible low- density non- calcified plaque (8 mm3). (A) shows a CCTA straight reformat with plaque identified, while (B) shows 
a straight reformat with a colour overlay of non- calcified plaque (yellow). (C) shows a curved multiplanar reformat. (D) shows a 
graphical output of the quantified plaque volume by AI- aided evaluation. dLAD, distal left anterior descending; LM, left main; 
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≥1.10, negative remodelling was defined as a ratio 
of <0.95 and intermediate remodelling was a ratio 
between 0.95 and 1.10.15
 ► HRP: HRPs were defined as coronary lesions with 
both LD- NCP and PR.7
 ► Other APCs: Plaque length measured uninterrupted 
plaque along the length of a vessel. Plaque diffusivity 
was the percent plaque along the length of a vessel 
divided by the total vessel length.16
Quantitative coronary angiography
Quantitative coronary angiography (QCA) was performed 
by a blinded core laboratory using an automated edge- 
detection algorithm by standard approaches as previously 
reported.17 Angiographic percent diameter stenosis, and 
lumen diameters of the proximal and distal reference 
segments were measured.
Statistical analysis
All statistical analyses were performed using SAS V.9.4 
(SAS, Cary, North Carolina). Continuous data are 
reported as mean±SD, and categorical variables are 
presented as absolute numbers with corresponding 
frequencies. Student’s t- test, Mann- Whitney test, χ2 and 
Fisher exact tests were used to compare the distribution 
of continuous and categorical variables, respectively.
Patient and public involvement statement
This is a retrospective study that analyses prospec-
tively collected de- identified multicentre data from the 
CREDENCE trial. Patients were recruited and consented 
for participation in the CREDENCE trial, but were not 
interactive with investigators conducting the substudy 
analysis. However, patients were involved in the design 
of the study to the extent that their invasive and non- 
invasive imaging was used to conduct this substudy, and 
study findings are aimed at improving clinical knowledge 
of cardiac disease in their cohort.
RESULTS
The study cohort was comprised of 303 patients whose 
mean age was 64.4±10.2 years. The cohort was 29% women, 
71% Asian and had a high prevalence of CAD risk factors 
including 64% with hypertension, 45% with dyslipidaemia 
and 48% with prior tobacco use (table 1). Nearly half of 
the patients (48%) demonstrated typical or atypical angina, 
while over one- third (35%) were asymptomatic. When 
stratifying by QCA there were significantly more women 
with non- obstructive (<50%) CAD (39% vs 22% p=0.001). 
Patients with obstructive stenosis (≥50%) were significantly 
more likely than patients with non- obstructive stenosis to 
have a family history of CAD and to have used tobacco, with 
Figure 3 A 74- year- old with coronary CT angiography (CCTA) undergoing artificial intelligence (AI)- aided evaluation of stenosis 
and quantitative atherosclerosis burden. The patient demonstrates right coronary artery obstructive stenosis (61%) with a high 
burden of plaque (796.8 mm3) consisting predominantly of calcified plaque (550.8 mm3). (A) shows a CCTA straight reformat 
with plaque identified, while (B) shows a straight reformat with a colour overlay of non- calcified plaque (yellow), and calcified 
plaque (blue). (C) shows a curved multiplanar reformat. (D) shows a graphical output of the quantified plaque volume by AI- 
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no differences noted for prevalence of hypertension, dyslip-
idaemia or diabetes (table 2). Among younger (age <65) 
versus older patients (age ≥65), hypertension was more 
commonly observed in older than younger patients (74% 
vs 53%). There were no significant differences in gender 
composition, dyslipidaemia, diabetes or symptoms between 
younger and older individuals.
Table 3 summarises CCTA findings evaluated by AI as 
a function of non- obstructive (<50%) and obstructive 
(≥50%) stenosis by QCA for patients <65 and ≥65 on a 
per- patient basis. In patients with both non- obstructive 
(<50%) and obstructive stenosis, patients ≥65 had overall 
significantly greater plaque volume, total plaque %PAV, 
and calcified plaque when compared with patients <65. In 
examining specific APCs, older patients had overall higher 
PV (792.7±486.1 mm3 vs 500.1+349.8 mm3; p<0.0001) across 
plaque components including higher calcified plaque 
(366.5±336.2 mm3 vs 148.0±187.5 mm3; p<0.0001) and 
calcified %PAV (4.6% vs 2.6%; p=0.01). However, younger 
patients with non- obstructive disease demonstrated a 
similar degree of NCP (243.0±220.2 mm3 vs 286.5±190.2 
mm3; p=NS) and LD- NCP (8.6±11.1 mm3 vs 8.9±12.9 mm3; 
p=NS) when compared with older patients. Obstructive 
lesions in patients >65 had higher PAV of calcified (8.1% 
vs 3.2%; p<0.0001); and NCP (9.1% vs 7.6%; p=0.007) than 
younger patients with obstructive lesions (table 3).
Further evaluating APCs on an individual lesion basis, 
table 4 shows the PV by AI- QCT of individual non- 
obstructive lesions was greater in patients ≥65 versus 
patients <65 (105.6 mm3 vs 60.5 mm3; p<0.005). However, 
non- obstructive lesions in patients <65 exhibit a greater 
proportion of %PAV (LD- NCP) (1.5% vs 0.7%; p=0.038), 






Age, years, mean (SD) 64.4 (10.2) 64.3 (10.2) 64.6 (10.2) 0.8
Female 88 (29%) 50 (39%) 38 (22%) 0.001
Hypertension 195 (64%) 79 (62%) 116 (66%) 0.41
Dyslipidaemia 135 (45%) 56 (44%) 79 (45%) 0.81
Diabetes 95 (31%) 38 (30%) 57 (33%) 0.59
Family history 59 (20%) 18 (14%) 41 (23%) 0.04
Tobacco use 146 (48%) 53 (41%) 93 (53%) 0.04
Symptoms
  Typical angina 109 (36%) 36 (28%) 73 (42%) 0.11
  Atypical 49 (16%) 23 (18%) 26 (15%)
  Non- cardiac 40 (13%) 19 (15%) 21 (12%)
  Asymptomatic 105 (35%) 50 (39%) 55 (31%)















Age, years, mean 
(SD)
55.7 (7) 71.9 (5) <0.001 56.1 (7) 71.9 (6) <0.0001 55.3 (7) 71.8 (5) <0.0001
Female 36 (26) 52 (32) 0.27 23 (37) 27 (41) 0.66 13 (17) 25 (26) 0.17
Hypertension 74 (53) 121 (74) <0.0001 33 (53) 46 (70) 0.05 41 (53) 75 (77) 0.001
Dyslipidaemia 56 (40) 79 (48) 0.17 24 (39) 32 (49) 0.26 32 (42) 47 (48) 0.40
Diabetes 38 (27) 57 (35) 0.17 17 (27) 21 (32) 0.59 21 (27) 36 (37) 0.18
Family history 35 (25) 24 (15) 0.02 13 (21) 5 (8) 0.03 22 (29) 19 (19) 0.15
Tobacco use 75 (54) 71 (43) 0.06 26 (42) 27 (41) 0.90 49 (64) 44 (45) 0.01
Symptoms 0.31 0.95 0.06
  Typical angina 52 (37) 57 (35) 18 (29) 18 (27) 34 (44) 39 (40)
  Atypical 25 (18) 24 (14) 10 (16) 13 (20) 15 (20) 11 (11)
  Non- cardiac 13 (9) 27 (16) 9 (15) 10 (15) 4 (5) 17 (17)
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Table 3 Per- patient adverse plaque characteristics by artificial intelligence enabled quantitative coronary computed 
tomographic angiography by non- obstructive versus obstructive angiographic stenosis stratified by age
Variable, mean (SD)
Non- obstructive (<50%) per- patient
(N=128)










PV, mm3 357.5 (379.3) 510.7 (206.2) 0.02 500.1 (349.8) 792.7 (486.1) <0.0001
LD- NCP, mm3 8.6 (11.1) 8.9 (12.9) 0.46 15.0 (15.3) 12.4 (15.8) 0.11
NCP, mm3 243.0 (220.2) 286.5 (190.2) 0.10 352.1 (266.8) 426.2 (262.7) 0.02
CP, mm3 114.5 (190.5) 224.2 (372.1) 0.007 148.0 (187.5) 366.5 (336.2) <0.0001
Total plaque %PAV 8.2 (7.3) 11.1 (8.6) 0.03 10.7 (6.9) 17.2 (9.7) <0.0001
LD- NCP %PAV 0.2 (0.2) 0.2 (0.3) 0.41 0.3 (0.3) 0.2 (0.2) 0.07
NCP %PAV 5.6 (4.4) 6.5 (4.0) 0.14 7.6 (5.1) 9.1 (4.7) 0.007
CP %PAV 2.6 (3.6) 4.6 (6.2) 0.01 3.2 ((4.0) 8.1 (7.0) <0.0001
% plaque calcified 25.3 (21.3) 33.9 (22.4) 0.21 26.6 (21.3) 42.5 (20.5) <0.0001
Remodelling index 1.30 (0.20) 1.35 (0.21) 0.50 1.38 (0.23) 1.40 (0.22) 0.44
Positive remodelling >1.1, n (%) 48 (79) 55 (83) 0.56 67 (88) 88 (90) 0.73
Intermediate remodelling, n (%) 10 (16) 10 (15) 9 (12) 10 (10)
Negative remodelling, n (%) 3 (5) 1 (2) 0 0
HRP (LD- NCP +PR), n (%) 43 (69) 51 (77) 0.31 61 (79) 79 (81) 0.82
Lesion length, mm 23.5 (13.7) 31.9 (21.1) 0.02 28.7 (14.8) 37.6 (19.6) <0.001
CP, calcified plaque; HRP, high risk plaque; LD- NCP, low- density non- calcified plaque; NCP, non- calcified plaque; %PAV, percent atheroma 
volume; PR, positive remodelling ; PV, plaque volume.
Table 4 Per- lesion adverse plaque characteristics by artificial intelligence enabled quantitative coronary computed 
tomographic angiography by non- obstructive versus obstructive angiographic stenosis stratified by age
Variable









PV, mm3 60.5 (79.8) 105.6 (140.5) 0.001 103.8 (134.5) 109.7 (131.4) 0.83
LD- NCP, mm3 1.6 (3.1) 2.0 (6.6) 0.56 4.2 (8.2) 2.6 (10.0) 0.26
NCP, mm3 38.4 (50.8) 56.2 (75.8) 0.058 74.6 (108.1) 61.5 (85.8) 0.33
CP, mm3 22.1 (39.1) 49.4 (86.8) 0.004 29.2 (51.5) 48.2 (72.7) 0.04
PAV (total plaque) 41.0 (17.4) 44.8 (16.8) 0.17 49.9 (18.6) 54.7 (16.5) 0.07
% PAV (LD- NCP) 1.5 (3.3) 0.7 (1.3) 0.038 2.0 (3.0) 1.2 (2.8) 0.12
% PAV (NCP) 25.6 (12.4) 25.2 (12.9) 0.81 33.1 (19.3) 30.5 (15.4) 0.32
% PAV (CP) 13.7 (15.7) 18.6 (18.1) 0.07 13.9 (15.6) 30.5 (15.4) 0.001
% Plaque calcified 28.0 (28.5) 36.8 (28.9) 0.06 27.3 (26.8) 38.2 (27.3) 0.007
Remodelling index 1.13 (0.20) 1.06 (0.21) 0.02 1.10 (0.28) 1.05 (0.28) 0.24
Positive remodeling >1.1 29 (41%) 34 (29%) 0.36 25 (33%) 29 (30%) 0.78
Intermediate remodelling 28 (39%) 46 (40%) 26 (34%) 27 (28%)
Negative remodelling 14 (20%) 36 (31%) 26 (34%) 42 (43%)
HRP (LD- NCP +PR) 34 (48%) 42 (36%) 0.16 31 (40%) 33 (34%) 0.40
Lesion length, mm 13.9 (10.4) 18.1 (15.6) 0.02 18.3 (15.5) 18.2 (15.1) 0.90
CP, calcified plaque; HRP, high risk plaque; LD- NCP, low- density non- calcified plaque; NCP, non- calcified plaque; PAV, per cent atheroma 
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near significantly higher volume of NCP in age <65 (38.4 
mm3 vs 56.2 mm3; p<0.058), as well as a higher remod-
elling index (1.13 vs 1.06; p=0.02) with shorter lesion 
length (13.9 mm vs 18.1 mm; p=0.02). An illustrative case 
of obstructive stenosis in a 39- year- old with high NCP and 
LD- NCP burden is shown in figure 1. An illustrative case 
of non- obstructive stenosis in a 55- year- old with high NCP 
is shown in figure 2. Age >65 patients with non- obstructive 
lesions exhibit higher calcified plaque (49.4 mm3 vs 22.1 
mm3; p=0.004) and near significant % plaque calcified 
(36.8% vs 28.0%; p=0.06) compared with patient <65. An 
illustrative case of calcified plaque in a 74- year- old with 
high calcified burden is shown in figure 3.
Online supplemental appendix C shows per- patient 
and per- lesion analysis within the younger and older age 
cohorts for non- obstructive and obstructive stenoses. In 
both younger and older individuals, PV and CP are higher 
for obstructive stenosis versus non- obstructive stenosis. In 
older adults, there was no difference between the volume 
of LD- NCP in non- obstructive and obstructive lesions, 
while calcified plaque was significantly higher in obstruc-
tive versus non- obstructive lesions (366.5 mm3 vs 224 mm3; 
p=0.01).
DISCUSSION
In this analysis of CREDENCE, we uniquely applied AI for 
quantitative plaque evaluation and add several important 
new observations to the expanding body of literature on 
APC identified by CCTA. Our study found that APCs of 
high- grade stenoses differ by age with patients <65 years 
exhibiting greater PV, LD- NCP, NCP and lesion length 
in obstructive lesions compared with non- obstructive 
lesions. Patients >65 years exhibited a greater burden of 
calcified plaque in both non- obstructive and obstructive 
stenoses. Furthermore, in patients >65 with obstructive 
stenosis, while there was a higher calcified and NCP 
burden, younger patients had similar LD- NCP as older 
patients with obstructive lesions.
Recent validation of the AI- guided approach applied 
in this study allows for accurate AI evaluation of stenosis 
as well allowing for quantification of PV to an order of 
3–5 mm3 that may not be readily identified by expert 
readers.12 18 19 This data extends atherosclerosis evalua-
tion beyond previous logistic regression models incorpo-
rating plaque as one of many variables defined by manual 
methods.20 In addition, the use of well- validated deep 
machine learning approaches allows for enhanced and 
rapid image processing. Previous validation data from 
our group has shown that this AI approach can perform 
whole heart atherosclerosis and stenosis evaluation in 
approximately 10 min, whereas manual approaches may 
take several hours to complete and be prone to variability.
Through this AI approach, we show that atheroscle-
rosis in younger adults with non- obstructive stenoses 
demonstrate comparable plaque characterisation when 
compared with older adults. This includes the presence 
of high- risk plaque features such as NCP, LD- NCP and 
PR that qualitatively portend, by SCCT expert consensus, 
a future risk of cardiovascular events.21 Importantly, AI 
identified a higher PAV of LD- NCP in younger individuals 
with non- obstructive atherosclerosis, a plaque type iden-
tified as highest risk by cardiac CT.22 These data affirm 
prior findings that younger patients have high volumes 
of non- calcified atherosclerosis with a higher degree of 
LD- NCP, while older patients develop a higher degree of 
calcified plaque in both non- obstructive and obstructive 
lesions.22 Lowenstern et al’s subanalysis of the PROMISE 
(Prospective Multicenter Imaging Study for Evaluation 
of Chest Pain) study also supports the finding that older 
patients have more calcified plaque.23 However, impor-
tantly, the study also showed that high calcium scores 
did not confer risk for MACE in older patients while it 
did conferred risk for MACE in individuals younger than 
65.23 The study does not comment on additional APCs 
like LD- NCP, but remains consistent with our findings 
and re- emphasises the benefit of addressing plaque char-
acteristics for prognostication for MACE at different ages. 
In our study, age stratification identified differences in 
overall plaque burden, which may help identify younger 
patients who may be at risk for future acute coronary 
syndrome (ACS) despite having non- obstructive stenoses.
While the literature on APCs and high- risk lesion assess-
ment is rapidly expanding, there is still limited infor-
mation regarding age- oriented plaque composition. In 
particular, identifying which younger adults are at risk for 
CAD remains challenging due to limitations in current 
risk calculators and insufficient data in this group.24 Addi-
tionally, limitations exist in identifying atherosclerosis via 
conventional approaches, such as stress testing, making 
younger adults less likely to be treated with preventive 
therapies. While Ruiz-García et al published a substudy 
of the PROSPECT (Prospective Natural History Study of 
Coronary Atherosclerosis) trial evaluating APCs of non- 
culprit lesions via intravascular ultrasound (IVUS) that 
concluded that patients older than 65 had greater plaque 
burden, necrotic core and dense calcium content than 
patients younger than 65 (regardless of gender),25 this 
study involved non- culprit lesions in patients who had 
already experienced ACS and could not be generalised to 
a younger population in the preventive stages of disease.
In the CCTA literature, an age- based study was recently 
conducted by Conte et al who evaluated a subgroup of 
patients from the ICONIC (Incident Coronary Syndromes 
Identified by Computed Tomography) trial to determine 
whether APCs of culprit lesions varied by age and showed 
that older patients had greater total PV, specifically calci-
fied plaque, as well as greater segment involvement and 
segment severity scores than younger patients.26 However, 
again, the study cohort was comprised of ACS patients and 
the lesion level analysis pertained specifically to culprit 
lesions, limiting the ability to generalise findings. Addi-
tionally, Kim et al initiated a substudy of the PARADIGM 
(Progression of AtheRosclerotic PlAque DetermIned by 
Computed TomoGraphic Angiography Imaging) trial, a 
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the rate of plaque progression, specifically densely calcified 
plaque, increased with age.27 The study’s intention was to 
identify gross trends in a middle- aged cohort (40–75 years), 
and to that end, whole heart plaque was evaluated while 
lesion- based changes were unaddressed.
While calcified plaque increases with age, a finding 
consistent with our data, this does not account for the 
high risk ACPs at younger ages that may be important for 
early screening.24 28 Our study findings suggest that the 
quantification of APCs associated within plaque identi-
fied by AI- QCT, namely, LD- NCP, NCP and PV and lesion 
length may also provide prognostic value when screening 
patients <65 years. Understanding this plaque phenotype 
also may allow for enhanced opportunities to understand 
and modulate the plaque phenotype through preventive 
therapies such as statins and newer agents such as PCSK- 9 
inhibition.29
This study is subject to limitations. While patients were 
enrolled prospectively from a large, multicentre clinical 
trial with evaluation by a blinded core laboratory, the evalu-
ation was post hoc and not powered to detect differences in 
plaque types. About one- third of the patients had demon-
strable atherosclerosis despite the absence of symptoms, 
which may not be fully representative of a stable chest 
pain population, but also represent a limitation in current 
guidelines for testing. Additionally, the CCTAs evaluated 
reflect a single point in time rather than a longitudinal 
period thereby limiting knowledge of plaque progression 
as reflected at various ages. Though coronary lesions are 
dynamic, changes in PV composition as a function of wors-
ening stenosis severity was not evaluated. Finally, we used 
angiographic coronary stenosis as a marker of CAD severity. 
While large- scale prognosis of AI- QCT defined quantitative 
plaque composition has not yet been performed, it remains 
the subject of future study in the upcoming CONFIRM2 
study (Coronary CT Angiography Evaluation for Clin-
ical Outcomes: An International Multicenter Registry; 
NCT04279496).
In sum, AI- QCT identifies a unique APC signature that 
differs by age with patients <65 years exhibiting greater PV, 
LD- NCP, NCP and lesion length in obstructive compared 
with non- obstructive lesions. While no difference in plaque 
composition was observed in obstructive stenoses for 
patients >65 years, older patients had greater CP volume 
and patients <65 had more NCP and LD- NCP. These 
findings have important implications for prognosticating 
younger and older adults with unique plaque phenotypes 
identified by AI- QCT that allows a foundation for AI- guided 
precision approaches to cardiovascular prevention.
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